Success Metrics

Clinical Success Rate
91.7%

Based on 11 completed trials

Completion Rate
92%(11/12)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_3
10
83%
Ph phase_1
1
8%
Ph phase_2
1
8%

Phase Distribution

1

Early Stage

1

Mid Stage

10

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
1(8.3%)
Phase 2Efficacy & side effects
1(8.3%)
Phase 3Large-scale testing
10(83.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

91.7%

11 of 12 finished

Non-Completion Rate

8.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(11)
Terminated(1)

Detailed Status

Completed11
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
91.7%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (8.3%)
Phase 21 (8.3%)
Phase 310 (83.3%)

Trials by Status

completed1192%
terminated18%

Recent Activity

0 active trials
Showing 5 of 12
completedphase_3

A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.

NCT00754988
completedphase_3

A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes

NCT00909597
completedphase_2

A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.

NCT00423501
completedphase_3

A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease

NCT01018173
completedphase_3

A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.

NCT00717457
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT00754988Phase 3

A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.

Completed
NCT00909597Phase 3

A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes

Completed
NCT00423501Phase 2

A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.

Completed
NCT01018173Phase 3

A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease

Completed
NCT00717457Phase 3

A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.

Completed
NCT01051011Phase 3

A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy

Terminated
NCT00809705Phase 3

A Study of the Effect of Taspoglutide on Gastric Emptying in Patients With Type 2 Diabetes

Completed
NCT00811460Phase 1

A Study of Taspoglutide in Type 2 Diabetic Patients

Completed
NCT00744367Phase 3

A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.

Completed
NCT00755287Phase 3

A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.

Completed
NCT00823992Phase 3

A Study of Taspoglutide Versus Placebo for the Treatment of Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy

Completed
NCT00744926Phase 3

A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12